Biocardia, CellProThera & SlngXpand Collaborates to Develop and Commercialize CD34+ Stem Cells in Singapore for Myocardial Infarction

 Biocardia, CellProThera & SlngXpand Collaborates to Develop and Commercialize CD34+ Stem Cells in Singapore for Myocardial Infarction

Biocardia, CellProThera & SlngXpand Collaborates to Develop and Commercialize CD34+ Stem Cells in Singapore for Myocardial Infarction

  Shots:

  • SlngXpand will conduct clinical studies of expanded in vitro expanded peripheral blood CD34+ stem cells, CellProThera will fund the clinical studies and to receive exclusive commercialization rights of Biocardia’s Helix Biotherapeutic Delivery System in Singapore
  • Biocardia to get royalties on sales of product from CellProThera. The expanded CD34+ stem cells are processed by StemXpand Technology and delivered by Helix Biotherapeutic Delivery System in patients under treatment for Myocardial Infarction
  • Biocardia’s Helix Biotherapeutic is percutaneous catheter delivery system for the delivery of cell and gene based therapies for cardiovascular disorders

Click here to read full press release/ article | Ref: BusinessWire | Image: MassDevice

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post